IncellDx Awarded Patent for Use of CCR5 Antagonist Maraviroc
23 Nov 2021 //
BUSINESSWIRE
IncellDx’s CCTC Partners with ARISE MD Integrative Medicine & Surgery
18 Nov 2021 //
BUSINESSWIRE
IncellDx to Study Maraviroc, a CCR5 antagonist, in a COVID-19 Ph2 Clinical Trial
20 Oct 2020 //
PRNEWSWIRE